Zenbexus (Iberdomide)

Iberdomide is a medicine used to treat multiple myeloma, a cancer of the plasma cells in the bone marrow, after earlier treatment. It is taken as a capsule by mouth together with other myeloma medicines. It works by helping break down proteins the cancer cells need and by boosting the immune system.

Brand names:Zenbexus
Medication

What people taking Zenbexus (Iberdomide) report

Every report comes from a Lived member, sent anonymously.

Have you tried Zenbexus (Iberdomide) for Multiple Myeloma?

NameHow it went

About Zenbexus (Iberdomide)

What It's For

Iberdomide, sold as Zenbexus, is a prescription capsule for adults with multiple myeloma, a cancer of the plasma cells in the bone marrow. It is used when myeloma has come back or stopped responding after at least one earlier treatment that included two standard types of myeloma medicine: a proteasome inhibitor, such as bortezomib, and an immunomodulatory drug, such as lenalidomide (Revlimid). Iberdomide is not used on its own. It is taken together with daratumumab and hyaluronidase (Darzalex Faspro), an antibody injection given under the skin, and dexamethasone, a steroid. This three-drug combination is sometimes shortened to IberDd. The FDA granted accelerated approval in 2026 based on how deeply the combination clears myeloma, not yet on whether it helps people live longer or stay in remission longer. Those results are still being collected, and full approval depends on them.

How It Works

Inside every cell, a protein called cereblon helps tag other proteins for disposal. Iberdomide binds to cereblon and redirects it toward two proteins, Ikaros and Aiolos, that myeloma cells rely on to survive and grow. Once these are tagged, the cell breaks them down, which slows or kills the cancer cells. The same change also affects immune cells. It increases the release of signals that activate the immune system and helps immune cells recognize and destroy myeloma. In laboratory studies, iberdomide strengthened daratumumab's ability to mark myeloma cells for attack, and it was active against myeloma cells that had become resistant to lenalidomide and pomalidomide (Pomalyst), older medicines of the same family. How well these laboratory findings carry over to each person's treatment varies.

Dosage & Administration

Iberdomide is taken by mouth once a day, at about the same time each day, with or without food. It follows a 28-day cycle: one capsule daily for the first 21 days, then a 7-day break. Daratumumab injections and dexamethasone follow their own schedules within the same cycle, and treatment continues for as long as it keeps the myeloma under control and side effects remain manageable. Swallow the capsule whole with water. Do not open, break or chew it, and keep it in its original bottle until you are ready to take it. If you touch a broken capsule or its powder, wash your skin right away with soap and water. If you miss a dose and fewer than 12 hours have passed, take it as soon as you remember. If more than 12 hours have passed, skip it and take the next dose at the usual time; do not double up. Pausing or lowering the dose is common. The care team may switch to a lower-strength capsule after side effects, with severe kidney problems, or when another medicine raises iberdomide levels in the body.

Side Effects

In the main study, the most common effects of the combination were colds and other upper respiratory infections, tiredness, muscle and bone pain, pneumonia, diarrhea, constipation, rash and sleep problems. Some people had trouble with balance, muscle weakness or walking, which the label groups as motor dysfunction. Low antibody levels (hypogammaglobulinemia) were also common, which adds to infection risk. The most frequent serious problem is a drop in neutrophils, the white blood cells that fight bacterial infection. Nine in ten people had low counts, and most had a severe drop at some point, so regular blood tests are part of treatment. Serious infections, including pneumonia, affected about 4 in 10 people, and some were fatal. Contact the care team promptly about a fever, chills or flu-like symptoms. Iberdomide also raises the risk of blood clots in the legs and lungs, as well as heart attack and stroke, so the care team usually prescribes a clot-prevention medicine alongside it. The risk remains even with that medicine. Tell the care team right away about swelling, pain, tenderness or redness in a leg. Call 911 for signs of a clot in the lungs or a heart attack (chest pain or sudden shortness of breath) or of a stroke (sudden numbness or weakness on one side of the body, sudden trouble speaking or seeing, sudden loss of balance, or a sudden severe headache or confusion). Balance or walking trouble that builds gradually is a known side effect; report it to the care team rather than treating it as an emergency. New, separate cancers (second primary cancers) occurred somewhat more often than with the comparison treatment, so the care team will watch for them over time.

Interactions & Warnings

Iberdomide can cause serious birth defects or the death of a developing baby, and it must not be taken during pregnancy. Because of this, it is available only through a restricted safety program (the Zenbexus REMS) that enrolls prescribers, pharmacies and patients. People who could become pregnant need two negative pregnancy tests before starting, regular tests during treatment, and either two forms of birth control used together or no heterosexual sex, from 4 weeks before the first dose until 4 weeks after the last. Anyone who misses a period, has unusual bleeding, stops birth control or thinks they may be pregnant should stop iberdomide and contact the prescriber right away. Iberdomide may pass into semen. Men must use a latex or synthetic condom during any sexual contact with a partner who could become pregnant, during treatment and for 4 weeks after, even after a vasectomy. No one taking iberdomide should donate blood, sperm or eggs during treatment or for 4 weeks after, and breastfeeding is not recommended. The body breaks down iberdomide mainly through an enzyme called CYP3A. Medicines that block this enzyme, such as the antifungal itraconazole, can raise iberdomide levels and side effects, while medicines that speed it up, such as the antibiotic rifampin, can lower levels enough to weaken treatment. Share a full list of medicines and supplements with the prescriber and pharmacist. Tell the care team about any past blood clot, heart attack or stroke, high blood pressure, high cholesterol, smoking, kidney problems or a current infection. These affect clot prevention, dosing and whether treatment should wait.

What to Expect

Treatment is ongoing rather than a fixed course. Each 28-day cycle brings blood count checks and myeloma tests, and the early months involve frequent visits for daratumumab injections. Most people in the main study needed at least one pause in iberdomide, usually for low white blood cell counts or infections, and about 3 in 10 had their dose lowered. These adjustments are a normal part of using the drug. The goal is a deep response. In the main study, about 41 percent of people taking the iberdomide combination reached complete response with no detectable myeloma on a highly sensitive test, called minimal residual disease (MRD) negativity, compared with about 21 percent on daratumumab, bortezomib and dexamethasone. Whether this deeper response translates into longer remissions or longer survival with this combination is still being studied. The study included people with one or two earlier treatments, and few of them had received daratumumab before. There is little information on how well it works for people whose disease no longer responds to daratumumab.

Questions to Ask Your Doctor

  1. 1.Why is the iberdomide combination a good fit for my myeloma compared with other second-line options?
  2. 2.How will we measure whether it is working, and will MRD testing be part of my monitoring?
  3. 3.What should I do if I get a fever, and do I need medicines to prevent infections or blood clots?
  4. 4.Do any of my current medicines or supplements interact with iberdomide?
  5. 5.What do the REMS pregnancy and contraception requirements mean for me and my partner?

Last reviewed • Oct 2026

Educational content, not medical advice.